# A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

Study · id `cardio:ct-nct01169090` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01169090](<https://clinicaltrials.gov/study/NCT01169090>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01169090

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 620 participants.

## Technical summary

Registry record NCT01169090. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 620 participants (planned count; ClinicalTrials.gov record NCT01169090, source copy `cardio:ctgov-nct01169090-2011-08-17`, retrieved 2026-10-26)
- Start date: 2010-07 (registry gives no type) (ClinicalTrials.gov record NCT01169090, source copy `cardio:ctgov-nct01169090-2011-08-17`, retrieved 2026-10-26)
- Primary completion: 2011-07 (actual) (ClinicalTrials.gov record NCT01169090, source copy `cardio:ctgov-nct01169090-2011-08-17`, retrieved 2026-10-26)
- Completion: 2011-08 (actual) (ClinicalTrials.gov record NCT01169090, source copy `cardio:ctgov-nct01169090-2011-08-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01169090, source copy `cardio:ctgov-nct01169090-2011-08-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01169090-2011-08-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
- Condition: Type 2 Diabetes
- Intervention (Drug): SK-0403
- Intervention (Drug): Placebo
- Intervention (Drug): Sitagliptin
- Lead sponsor: Kowa Research Institute, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Kowa Research Institute, Inc. (`cardio:org-kowa-research-institute-inc`)

## Provenance

Content hash: 49368dbb9ba6e7fb80a54d831f2f6d6e00e2e1ea88c416c7da45f79f48b28d3a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
